SCHEMBL4150121

SCHEMBL4150121

CC(=O)c1cc(C#N)cc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
XDH P47989 1/20 0.50
SLC22A12 Q96S37 1/20 0.50
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 3/20 0.44
MAOB P27338 2/20 0.43
KDM4E B2RXH2 3/20 0.41
CA9 Q16790 2/20 0.41
CYP1A2 P05177 2/20 0.41
CA12 O43570 1/20 0.41
NT5E P21589 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NSD2 O96028 1/20 0.41
POLB P06746 1/20 0.41
MCL1 Q07820 1/20 0.41
RAB9A P51151 2/20 0.39
F2 P00734 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL758397 0.87 CA1 (0.56) CA1CA2XDHSLC22A12ALDH1A1
SCHEMBL756422 0.85 XDH (0.62) CA1CA2XDHSLC22A12ALDH1A1
SCHEMBL26337729 0.83 KDM4E (0.53) CA1CA2XDHSLC22A12ALDH1A1
SCHEMBL2483533 0.83 KDM4E (0.52) CA1CA2XDHSLC22A12ALDH1A1
SCHEMBL38665356 0.75 MAPT (0.62) ALDH1A1MAPTHPGDMAOBKDM4E
SCHEMBL25986589 0.75 MAPT (0.62) ALDH1A1MAPTHPGDMAOBKDM4E
SCHEMBL6362640 0.75 CYP1A2 (0.53) ALDH1A1MAPTHPGDMAOBKDM4E
SCHEMBL10909445 0.75 CDC25B (0.60) ALDH1A1MAPTHPGDMAOBKDM4E
SCHEMBL7304752 0.74 CA1 (0.61) CA1CA2XDHSLC22A12ALDH1A1
SCHEMBL50624 0.74 ALDH1A1 (0.56) ALDH1A1MAPTHPGDMAOBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040706-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2015-05-26 US disclosed
US-9040706-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2015-05-26 US disclosed
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2014-03-20 US disclosed
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2014-03-20 US disclosed
EP-1836201-B2 PYRROLIDINE INHIBITORS OF IAP GENENTECH INC (US) 2013-09-04 EP disclosed
EP-1836201-B1 PYRROLIDINE INHIBITORS OF IAP GENENTECH INC (US) 2010-08-11 EP disclosed
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-12-24 US disclosed
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-12-24 US disclosed
CN-100534983-C Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them GLAXO GROUP LTD (GB) 2009-09-02 CN disclosed
US-20090192194-A1 Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them ALVARO GIUSEPPE 2009-07-30 US disclosed
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-07-09 US disclosed
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-07-09 US disclosed
US-20070073061-A1 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
CN-1819995-A Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them GLAXO GROUP LTD (GB) 2006-08-16 CN disclosed
EP-1622871-A1 CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 2006-02-08 EP disclosed
WO-2004099143-A1 CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 CA1 2623/4885CA2 2713/4885XDH 2283/4885
US-20070073061-A1 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them SLC6A4, OPRL1, HCRTR1 CA1 2530/4885CA2 1755/4885XDH 3340/4885
US-20090192194-A1 Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them SLC6A4, OPRL1, HCRTR1 CA1 2530/4885CA2 1755/4885XDH 3340/4885
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 CA1 2623/4885CA2 2713/4885XDH 2283/4885
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 CA1 2623/4885CA2 2713/4885XDH 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.